

KEWAUNEE SCIENTIFIC CORP /DE/  
Form 10-Q  
March 10, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended January 31, 2016**

**or**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission file number 0-5286**

**KEWAUNEE SCIENTIFIC CORPORATION**  
**(Exact name of registrant as specified in its charter)**

|   |   |
|---|---|
| <b>Delaware</b><br><b>(State or other jurisdiction of</b>                             | <b>38-0715562</b><br><b>(IRS Employer</b> |
| <b>incorporation or organization)</b>   | <b>Identification No.)</b>                |
| <b>2700 West Front Street</b>   |   |
| <b>Statesville, North Carolina</b><br><b>(Address of principal executive offices)</b> | <b>28677-2927</b><br><b>(Zip Code)</b>    |
| <b>Registrant's telephone number, including area code: (704) 873-7202</b>             |   |

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

|  |   |
|--|---|
| Large accelerated filer <input type="checkbox"/>   | Accelerated filer <input type="checkbox"/>                    |
| Non-accelerated filer <input type="checkbox"/> (Do not check if a smaller reporting company) | Smaller reporting company <input checked="" type="checkbox"/> |

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes  No

As of March 7, 2016, the registrant had outstanding 2,684,580 shares of Common Stock.

---

**KEWAUNEE SCIENTIFIC CORPORATION**

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2016

|  | <b>Page Number</b> |
|--|--------------------|
| <b><u>PART I. FINANCIAL INFORMATION</u></b>  |                    |
| Item 1. <u>Financial Statements</u>  |                    |
| <u>Consolidated Statements of Operations (unaudited) Three and nine months ended January 31, 2016 and 2015</u>           | 1                  |
| <u>Consolidated Statements of Comprehensive Income (unaudited) Three and nine months ended January 31, 2016 and 2015</u> | 2                  |
| <u>Consolidated Statement of Stockholders Equity (unaudited) Nine months ended January 31, 2016</u>                      | 3                  |
| <u>Consolidated Balance Sheets January 31, 2016 (unaudited) and April 30, 2015</u>                                       | 4                  |
| <u>Consolidated Statements of Cash Flows (unaudited) Nine months ended January 31, 2016 and 2015</u>                     | 5                  |
| <u>Notes to Consolidated Financial Statements</u>  | 6                  |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>                     | 8                  |
| <u>Review by Independent Registered Public Accounting Firm</u>   | 11                 |
| <u>Report of Independent Registered Public Accounting Firm</u>   | 12                 |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>  | 13                 |
| Item 4. <u>Controls and Procedures</u>   | 13                 |
| <b><u>PART II. OTHER INFORMATION</u></b>   |                    |
| Item 6. <u>Exhibits</u>  | 14                 |
| <u>SIGNATURE</u>   | 15                 |

## Part 1. Financial Information

## Item 1. Financial Statements

*Kewaunee Scientific Corporation*

## Consolidated Statements of Operations

*(Unaudited)**(in thousands, except per share data)*

|   | Three months<br>ended<br>January 31 |           | Nine months ended<br>January 31 |           |
|---|-------------------------------------|-----------|---------------------------------|-----------|
|   | 2016                                | 2015      | 2016                            | 2015      |
| Net sales   | \$ 32,410                           | \$ 27,754 | \$ 94,536                       | \$ 88,546 |
| Costs of products sold  | 26,922                              | 23,298    | 77,673                          | 72,120    |
| Gross profit  | 5,488                               | 4,456     | 16,863                          | 16,426    |
| Operating expenses  | 4,441                               | 3,872     | 13,163                          | 12,170    |
| Operating earnings  | 1,047                               | 584       | 3,700                           | 4,256     |
| Other income  | 109                                 | 134       | 296                             | 385       |
| Interest expense  | (83)                                | (91)      | (236)                           | (274)     |
| Earnings before income taxes  | 1,073                               | 627       | 3,760                           | 4,367     |
| Income tax expense  | 225                                 | 109       | 1,242                           | 1,361     |
| Net earnings  | 848                                 | 518       | 2,518                           | 3,006     |
| Less: net earnings attributable to the noncontrolling interest                      | 18                                  | 34        | 53                              | 86        |
| Net earnings attributable to Kewaunee Scientific Corporation                        | \$ 830                              | \$ 484    | \$ 2,465                        | \$ 2,920  |
| Net earnings per share attributable to Kewaunee Scientific Corporation stockholders |                                     |           |                                 |           |
| Basic   | \$ 0.31                             | \$ 0.18   | \$ 0.93                         | \$ 1.11   |
| Diluted   | \$ 0.31                             | \$ 0.18   | \$ 0.92                         | \$ 1.10   |
| Weighted average number of common shares outstanding                                |                                     |           |                                 |           |
| Basic   | 2,682                               | 2,628     | 2,661                           | 2,625     |
| Diluted   | 2,699                               | 2,659     | 2,683                           | 2,656     |

*See accompanying notes to consolidated financial statements.*

*Kewaunee Scientific Corporation*

## Consolidated Statements of Comprehensive Income

*(Unaudited)**(in thousands)*

|  | <b>Three months ended</b> |             | <b>Nine months ended</b> |             |
|--|---------------------------|-------------|--------------------------|-------------|
|  | <b>January 31</b>         |             | <b>January 31</b>        |             |
|  | <b>2016</b>               | <b>2015</b> | <b>2016</b>              | <b>2015</b> |
| Net earnings   | \$ 848                    | \$ 518      | \$ 2,518                 | \$ 3,006    |
| Other comprehensive income (loss), net of tax:                         |                           |             |                          |             |
| Foreign currency translation adjustments                               | (221)                     | (130)       | (435)                    | (246)       |
| Change in fair value of cash flow hedge                                |                           | (17)        | 11                       | (15)        |
| Other comprehensive income (loss)                                      | (221)                     | (147)       | (424)                    | (261)       |
| Comprehensive income, net of tax                                       | 627                       | 371         | 2,094                    | 2,745       |
| Less: comprehensive income attributable to the noncontrolling interest | 18                        | 34          | 53                       | 86          |
| Comprehensive income attributable to Kewaunee Scientific Corporation   | \$ 609                    | \$ 337      | \$ 2,041                 | \$ 2,659    |

*See accompanying notes to consolidated financial statements.*

*Kewaunee Scientific Corporation*

## Consolidated Statement of Stockholders Equity

*(Unaudited)**(in thousands, except shares and per share data)*

|   | Common<br>Stock | Additional<br>Paid-in<br>Capital | Treasury<br>Stock | Retained<br>Earnings | Accumulated<br>Other<br>Comprehensive<br>Income<br>(Loss) | Total<br>Stockholders<br>Equity |
|---|-----------------|----------------------------------|-------------------|----------------------|---|---------------------------------|
| <i>\$ in thousands, except per share amounts</i>                |                 |                                  |                   |                      |   |                                 |
| Balance at April 30, 2015                                       | \$ 6,583        | \$ 1,841                         | \$ (53)           | \$ 34,385            | \$ (7,880)  | \$ 34,876                       |
| Net earnings attributable to Kewaunee<br>Scientific Corporation |                 |                                  |                   | 2,465                |   | 2,465                           |
| Other comprehensive income (loss)                               |                 |                                  |                   |                      | (424)   | (424)                           |
| Cash dividends paid, \$0.38 per share                           |                 |                                  |                   | (1,012)              |   | (1,012)                         |
| Stock options exercised, 84,000 shares                          | 137             | 322                              |                   |                      |   | 459                             |
| Stock based compensation  |                 | 146                              |                   |                      |   | 146                             |
| Balance at January 31, 2016                                     | \$ 6,720        | \$ 2,309                         | \$ (53)           | \$ 35,838            | \$ (8,304)  | \$ 36,510                       |

*See accompanying notes to consolidated financial statements.*

*Kewaunee Scientific Corporation*

## Consolidated Balance Sheets

*(in thousands, except per share data)*

|  | <b>January 31,<br/>2016<br/>(Unaudited)</b> | <b>April 30,<br/>2015</b> |
|--|---|---------------------------|
| <b><u>Assets</u></b>   |   |                           |
| Current Assets:  |   |                           |
| Cash and cash equivalents  | \$ 3,709                                    | \$ 3,044                  |
| Restricted cash  | 1,444                                       | 2,276                     |
| Receivables, less allowance: \$171; \$171, on each respective date | 29,409                                      | 29,106                    |
| Inventories  | 16,154                                      | 12,745                    |
| Deferred income taxes  | 814   | 856                       |
| Prepaid expenses and other current assets                          | 891   | 735                       |
| <b>Total Current Assets</b>  | <b>52,421</b>                               | <b>48,762</b>             |
| Property, plant and equipment, at cost                             | 49,798                                      | 48,167                    |
| Accumulated depreciation   | (35,417)                                    | (33,644)                  |
| <b>Net Property, Plant and Equipment</b>                           | <b>14,381</b>                               | <b>14,523</b>             |
| Deferred income taxes  | 2,470                                       | 2,468                     |
| Other  | 3,567                                       | 3,737                     |
| <b>Total Other Assets</b>  | <b>6,037</b>                                | <b>6,205</b>              |
| <b>Total Assets</b>  | <b>\$ 72,839</b>                            | <b>\$ 69,490</b>          |
| <b><u>Liabilities and Equity</u></b>                               |   |                           |
| Current Liabilities:   |   |                           |
| Short-term borrowings and interest rate swaps                      | \$ 5,538                                    | \$ 4,955                  |
| Current portion of long-term debt                                  | 421   | 421                       |
| Accounts payable   | 12,215                                      | 11,232                    |
| Employee compensation and amounts withheld                         | 1,813                                       | 1,882                     |
| Deferred revenue   | 683   | 216                       |
| Other accrued expenses   | 2,210                                       | 2,349                     |
| <b>Total Current Liabilities</b>                                   | <b>22,880</b>                               | <b>21,055</b>             |
| Long-term debt   | 3,455                                       | 3,771                     |
| Accrued pension and deferred compensation costs                    | 9,712                                       | 9,465                     |
| <b>Total Liabilities</b>   | <b>36,047</b>                               | <b>34,291</b>             |
| Commitments and Contingencies                                      |   |                           |
| Equity:  |   |                           |
|  | 6,720                                       | 6,583                     |

Edgar Filing: KEWAUNEE SCIENTIFIC CORP /DE/ - Form 10-Q

|  |           |           |
|--|-----------|-----------|
| Common Stock, \$2.50 par value, Authorized 5,000 shares; Issued 2,688 shares;<br>2,633 shares; Outstanding - 2,685 shares; 2,630 shares, on each respective date |           |           |
| Additional paid-in-capital   | 2,309     | 1,841     |
| Retained earnings  | 35,838    | 34,385    |
| Accumulated other comprehensive loss   | (8,304)   | (7,880)   |
| Common stock in treasury, at cost, 3 shares, on each date  | (53)      | (53)      |
| Total Kewaunee Scientific Corporation Stockholders Equity  | 36,510    | 34,876    |
| Noncontrolling interest  | 282       | 323       |
| Total Equity   | 36,792    | 35,199    |
| Total Liabilities and Equity   | \$ 72,839 | \$ 69,490 |

*See accompanying notes to consolidated financial statements.*



*Kewaunee Scientific Corporation*

## Consolidated Statements of Cash Flows

*(Unaudited)**(in thousands)*

|   | <b>Nine months ended<br/>January 31</b> |                 |
|---|---|-----------------|
|   | <b>2016</b>                             | <b>2015</b>     |
| <b><i>Cash flows from operating activities:</i></b>                                 |   |                 |
| Net earnings  | \$ 2,518                                | \$ 3,006        |
| Adjustments to reconcile net earnings to net cash provided by operating activities: |   |                 |
| Depreciation  | 1,850                                   | 1,900           |
| Bad debt provision  | 7                                       | 34              |
| Stock based compensation expense  | 146                                     | 154             |
| Provision for deferred income tax expense   | 40                                      | (71)            |
| Change in assets and liabilities:   |   |                 |
| Increase in receivables   | (310)                                   | (1,623)         |
| Increase in inventories   | (3,409)                                 | (492)           |
| Increase in accounts payable and other accrued expenses                             | 1,663                                   | 4,022           |
| Increase in deferred revenue  | 467                                     | 159             |
| Other, net  | 164                                     | (750)           |
| Net cash provided by operating activities   | 3,136                                   | 6,339           |
| <b><i>Cash flows from investing activities:</i></b>                                 |   |                 |
| Capital expenditures  | (1,708)                                 | (2,135)         |
| Decrease (increase) in restricted cash  | 832                                     | (2,156)         |
| Net cash used in investing activities   | (876)                                   | (4,291)         |
| <b><i>Cash flows from financing activities:</i></b>                                 |   |                 |
| Dividends paid  | (1,012)                                 | (919)           |
| Dividends paid to noncontrolling interest in subsidiaries                           | (75)                                    | (38)            |
| Increase (decrease) in short-term borrowings and interest rate swaps                | 583                                     | (2,114)         |
| Payments on long-term debt  | (316)                                   | (316)           |
| Payment toward purchase of noncontrolling interest in subsidiary                    | (888)                                   | (888)           |
| Net proceeds from exercise of stock options (including tax benefit)                 | 459                                     | 33              |
| Net cash used in financing activities   | (1,249)                                 | (4,242)         |
| Effect of exchange rate changes on cash   | (346)                                   | (191)           |
| <b><i>Increase (decrease) in cash and cash equivalents</i></b>                      | <b>665</b>                              | <b>(2,385)</b>  |
| <b><i>Cash and cash equivalents, beginning of period</i></b>                        | <b>3,044</b>                            | <b>6,248</b>    |
| <b><i>Cash and cash equivalents, end of period</i></b>                              | <b>\$ 3,709</b>                         | <b>\$ 3,863</b> |

*See accompanying notes to consolidated financial statements.*

Kewaunee Scientific Corporation

Notes to Consolidated Financial Statements

(unaudited)

A. Financial Information

The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the Company) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim consolidated financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the consolidated financial statements and notes included in the Company's 2015 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The consolidated balance sheet as of April 30, 2015 included in this interim period filing has been derived from the audited financial statements at that date, but does not include all of the information and related notes required by generally accepted accounting principles (GAAP) for complete financial statements.

The preparation of the interim consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

B. Summary of Significant Accounting Policies

**Insurance** Effective January 1, 2016, the Company moved from a fully insured health care program to that of a self-insured program. The Company has also purchased specific stop-loss insurance to limit claims above certain amounts. The Company accrues estimated losses using actuarial models and assumptions based on historical loss experience. The Company records the insurance reserve within other accrued expenses on the consolidated balance sheets.

C. Earnings Per Share

Basic earnings per share is based on the weighted average number of common shares outstanding during the three and nine month periods. Diluted earnings per share reflects the assumed exercise and conversion of outstanding options under the Company's stock option plans, except when options have an anti-dilutive effect. Options to purchase 111,400 shares were not included in the computation of diluted earnings per share for the three and nine month periods ended January 31, 2016, because the option exercise prices were greater than the average market price of the common shares at that date, and accordingly, such options would have an anti-dilutive effect. Options to purchase 70,800 shares were not included in the computation of diluted earnings per share for the three and nine month periods ended January 31, 2015, because the effect would be anti-dilutive.

D. Inventories

Inventories consisted of the following (in thousands):

|                   | <b>January 31, 2016</b> | <b>April 30, 2015</b> |
|-------------------|-------------------------|-----------------------|
| Finished products | \$ 4,117                | \$ 2,936              |
| Work in process   | 1,633                   | 1,422                 |
| Raw materials     | 10,404                  | 8,387                 |
|                   | \$ 16,154               | \$ 12,745             |

For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim consolidated financial statements in the period in which they occur.

**E. Segment Information**

The following table provides financial information by business segments for the three and nine months ended January 31, 2016 and 2015 (in thousands):

|  | <b>Domestic<br/>Operations</b> | <b>International<br/>Operations</b> | <b>Corporate</b> | <b>Total</b> |
|--|--------------------------------|-------------------------------------|------------------|--------------|
| <b>Three months ended January 31, 2016</b> |                                |                                     |                  |              |
| Revenues from external customers           | \$ 25,423                      | \$ 6,987                            | \$               | \$ 32,410    |
| Intersegment revenues                      | 1,196                          | 421                                 | (1,617)          |              |
| Earnings (loss) before income taxes        | 1,586                          | 702                                 | (1,215)          | 1,073        |
| <b>Three months ended January 31, 2015</b> |                                |                                     |                  |              |
| Revenues from external customers           | \$ 20,025                      | \$ 7,729                            | \$               | \$ 27,754    |
| Intersegment revenues                      | 501                            | 697                                 | (1,198)          |              |
| Earnings (loss) before income taxes        | 264                            | 1,046                               | (683)            | 627          |

|   | <b>Domestic<br/>Operations</b> | <b>International<br/>Operations</b> | <b>Corporate</b> | <b>Total</b> |
|---|--------------------------------|-------------------------------------|------------------|--------------|
| <b>Nine months ended January 31, 2016</b> |                                |                                     |                  |              |
| Revenues from external customers          | \$ 76,017                      | \$ 18,519                           | \$               | \$ 94,536    |
| Intersegment revenues                     | 1,642                          | 1,694                               | (3,336)          |              |
| Earnings (loss) before income taxes       | 5,346                          | 2,002                               | (3,588)          | 3,760        |
| <b>Nine months ended January 31, 2015</b> |                                |                                     |                  |              |
| Revenues from external customers          | \$ 67,902                      | \$ 20,644                           | \$               | \$ 88,546    |
| Intersegment revenues                     | 1,407                          | 1,603                               | (3,010)          |              |
| Earnings (loss) before income taxes       | 4,526                          | 2,519                               | (2,678)          | 4,367        |

**F. Defined Benefit Pension Plans**

The Company has non-contributory defined benefit pension plans. These plans were amended as of April 30, 2005, no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. Contributions of \$64,000 were paid to the plans during the nine months ended January 31, 2016, and the Company does not expect any contributions to be paid to the plans during the remainder of the fiscal year. Contributions of \$775,000 were made during the nine months ended January 31, 2015.

Pension expense consisted of the following (in thousands):

|                                     | <b>Three months ended<br/>January 31,<br/>2016</b> | <b>Three months ended<br/>January 31,<br/>2015</b> |
|-------------------------------------|--|--|
| Service cost                        | \$ -0-   | \$ -0-   |
| Interest cost                       | 224  | 223  |
| Expected return on plan assets      | (334)  | (331)  |
| Recognition of net loss             | 329  | 233  |
| <b>Net periodic pension expense</b> | <b>\$ 219</b>                                      | <b>\$ 125</b>                                      |

|                                     | <b>Nine months ended<br/>January 31,<br/>2016</b> | <b>Nine months ended<br/>January 31,<br/>2015</b> |
|-------------------------------------|---|---|
| Service cost                        | \$ -0-  | \$ -0-  |
| Interest cost                       | 684   | 670   |
| Expected return on plan assets      | (1,022)   | (993)   |
| Recognition of net loss             | 917   | 700   |
| <b>Net periodic pension expense</b> | <b>\$ 579</b>                                     | <b>\$ 377</b>                                     |

## **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The Company's 2015 Annual Report to Stockholders contains management's discussion and analysis of financial condition and results of operations as of and for the year ended April 30, 2015. The following discussion and analysis describes material changes in the Company's financial condition since April 30, 2015. The analysis of results of operations compares the three and nine months ended January 31, 2016 with the comparable periods of the prior year.

### Results of Operations

Sales for the three months ended January 31, 2016 were \$32,410,000, an increase of 17% from sales of \$27,754,000 in the comparable period of the prior year. Sales from Domestic Operations were \$25,423,000, up from \$20,025,000 in the comparable period of the prior year. The increase in Domestic Operations sales resulted from stronger than typical third quarter opportunities in the laboratory furniture and casework marketplace. Sales from International Operations were \$6,987,000, down from \$7,729,000 in the comparable period of the prior year, due to a large order shipped in the prior year period that did not repeat.

Sales for the nine months ended January 31, 2016 were \$94,536,000, up 7% from sales of \$88,546,000 in the same period last year. Domestic Operations sales for the nine-month period were \$76,017,000, up from sales of \$67,902,000 in the same period last year. International Operations sales were \$18,519,000, down from sales of \$20,644,000 in the same period last year.

The order backlog was \$95.2 million at January 31, 2016, as compared to \$92.4 million at October 31, 2015 and \$78.0 million at January 31, 2015.

The gross profit margin for the three months ended January 31, 2016 was 16.9% of sales, as compared to 16.1% of sales in the comparable quarter of the prior year. The increase in the margin was the result of a favorable product mix. The gross profit margin for the nine months ended January 31, 2016 was 17.8% of sales, as compared to 18.6% in the comparable period of the prior year.

Operating expenses for the three months ended January 31, 2016 were \$4,441,000, or 13.7% of sales, as compared to \$3,872,000, or

14.0% of sales, in the comparable period of the prior year. Operating expenses for the three months ended January 31, 2016 reflect

nonrecurring expenses of \$154,000 related to the retirement and replacement of a key executive, an increase of \$247,000 in incentive compensation and a \$94,000 increase in pension expense when compared to the prior period. Operating expenses for the nine months ended January 31, 2016 were \$13,163,000, or 13.9% of sales, as compared to \$12,170,000, or 13.7% of sales in the comparable period of the prior year. Operating expenses for the nine months ended January 31, 2016 reflect nonrecurring expenses of \$678,000 related to the retirement and replacement of a key executive, and a \$202,000 increase in pension expense.

Interest expense was \$83,000 and \$236,000 for the three and nine months ended January 31, 2016, respectively, as compared to \$91,000 and \$274,000 for the comparable periods of the prior year. The decreases for the current year periods resulted primarily from lower borrowing levels.

Income tax expense of \$225,000 was recorded for the three months ended January 31, 2016, as compared to income tax expense of \$109,000 recorded for the comparable period of the prior year. Income tax expense of \$1,242,000 was recorded for the nine months ended January 31, 2016, as compared to income tax expense of \$1,361,000 recorded for the comparable period of the prior year. The effective tax rates were 21.0% and 17.4% for each of the three-month periods ended January 31, 2016 and 2015, respectively. The effective tax rates were 33.0% and 31.2% for the nine

months ended January 31, 2016 and 2015, respectively. The effective tax rates for the three month periods ended January 31, 2016 and 2015 were favorably impacted due to the reinstatement of the federal research and development (R&D) tax credit in January 2016 retroactive to 2015 and January 2015 retroactive to 2014. The cumulative impact of these credits was included in the third quarter effective rate calculation for each fiscal year. The increase in the effective rate for the current three month period compared to the prior year was primarily due the higher ratio of pretax earnings recorded at the statutory tax rate. The higher effective tax rate for the current year periods resulted from a higher ratio of pretax earnings attributable to subsidiaries located in geographic locations with higher income tax rates as compared to the comparable periods of the prior year.

Noncontrolling interests related to the Company's subsidiary that is not 100% owned by the Company reduced net earnings by \$18,000 for the three months ended January 31, 2016, as compared to \$34,000 for the comparable period of the prior year. Net earnings were reduced by \$53,000 and \$86,000 for the nine months ended January 31, 2016 and 2015, respectively. The changes in the amounts between each of these periods were directly attributable to changes in the amounts of net income reported for the Company's one subsidiary that is not 100% owned by the Company.

Net earnings of \$830,000, or \$0.31 per diluted share, were reported for the three months ended January 31, 2016, compared to net earnings of \$484,000, or \$0.18 per diluted share, in the prior year period. Net earnings of \$2,465,000, or \$0.92 per diluted share, were reported for the nine months ended January 31, 2016, compared to net earnings of \$2,920,000, or \$1.10 per diluted share, for the same period last year.



---

## Liquidity and Capital Resources

Historically, the Company's principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company's revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancellable operating leases or capital leases. The Company believes that these sources will be sufficient to support ongoing business requirements in the current fiscal year, including capital expenditures.

The Company had working capital of \$29,541,000 at January 31, 2016, compared to \$27,707,000 at April 30, 2015. The ratio of current assets to current liabilities was 2.3-to-1.0 at January 31, 2016 and April 30, 2015. At January 31, 2016, advances of \$4,808,000 were outstanding under the Company's bank revolving credit facility, as compared to advances of \$4,583,000 outstanding as of April 30, 2015. The Company had standby letters of credit outstanding of \$4,210,000 at January 31, 2016, and April 30, 2015. Amounts available under the \$20 million revolving credit facility were \$11.0 million and \$11.2 million at January 31, 2016 and April 30, 2015, respectively. Total bank borrowings were \$9,414,000 at January 31, 2016, as compared to \$9,147,000 at April 30, 2015.

The Company's operations provided cash of \$3,136,000 during the nine months ended January 31, 2016. Cash was primarily provided from earnings and an increase in accounts payable and other accrued expenses of \$1,663,000, and deferred revenue of \$467,000, which was partially offset by an increase in accounts receivable of \$310,000, and an increase in inventories of \$3,409,000. The Company's operations provided cash of \$6,339,000 during the nine months ended January 31, 2015. Cash was primarily provided from earnings and an increase in accounts payable and other accrued expense of \$4,022,000, which was partially offset by an increase in accounts receivable of \$1,623,000, and an increase in inventories of \$492,000. The large increase in accounts payable and accrued expenses in the prior year period was primarily attributable to the start-up of a large international project.

During the nine months ended January 31, 2016, net cash of \$876,000 was used in investing activities for capital expenditures of \$1,708,000, offset by a decrease in restricted cash of \$832,000. This compares to the net use of cash of \$4,291,000 for investing activities in the comparable period of the prior year for capital expenditures of \$2,135,000, and an increase in restricted cash of \$2,156,000.

The Company's financing activities used cash of \$1,249,000 during the nine months ended January 31, 2016 for the final payment of \$888,000 toward the purchase of the noncontrolling interest in a foreign subsidiary, cash dividends of \$1,012,000 paid to stockholders, cash dividends of \$75,000 paid to minority interest holders, and payments of \$316,000 on long-term debt, partially offset by an increase in short-term borrowings of \$583,000 and net proceeds of \$459,000 from the exercise of stock options. The Company's financing activities used cash of \$4,242,000 during the nine months ended January 31, 2015 for payment of \$888,000 for the second installment toward the purchase of the noncontrolling interest in a foreign subsidiary, repayment of short-term borrowings of \$2,114,000, cash dividends of \$919,000 paid to stockholders, cash dividends of \$38,000 paid to minority interest holders, and payments of \$316,000 on long-term debt.

## Outlook

The Company's ability to predict future demand for its products continues to be limited given its role as subcontractor or supplier to dealers for subcontractors. Demand for the Company's products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Company's earnings are also impacted by fluctuations in prevailing pricing for projects in the laboratory construction marketplace and increased costs of raw materials, including stainless steel, wood, and epoxy resin, and whether the Company is able to increase product prices to customers in amounts that correspond to such increases without materially and adversely affecting sales. Additionally, since prices are normally quoted on a firm basis in the industry, the Company bears the burden of possible increases in labor and material costs between the quotation of an order and delivery of a product. Looking forward, the Company expects fiscal year 2016 to be a profitable year for the

Company.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This report contains statements that the Company believes to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this report, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as anticipate, estimate, expect, project, intend, plan, predict, believe and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to, competitive and general economic conditions, both domestically and internationally; changes in customer demands; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency

fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; and acts of terrorism, war, governmental action, natural disasters and other Force Majeure events. Many important factors that could cause such a difference are described under the caption "Risk Factors" in Item 1A in the Company's 2015 Annual Report on Form 10-K. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

A review of the interim consolidated financial information included in this Quarterly Report on Form 10-Q for each of the three and nine month periods ended January 31, 2016 and January 31, 2015 has been performed by Cherry Bekaert LLP, the Company's independent registered public accounting firm. Their report on the interim consolidated financial information follows.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have reviewed the accompanying consolidated balance sheet of Kewaunee Scientific Corporation and its subsidiaries (the Company) as of January 31, 2016, the related consolidated statements of operations, and comprehensive income for the three-month and nine-month periods ended January 31, 2016 and 2015, the related consolidated statement of stockholders' equity for the nine-month period ended January 31, 2016, and the related consolidated statements of cash flows for the nine-month periods ended January 31, 2016 and 2015. These interim consolidated financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the interim consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of April 30, 2015, and the related consolidated statements of operations, comprehensive income and stockholders' equity, and cash flows for the year then ended (not presented herein) and in our report dated July 20, 2015, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of April 30, 2015 is fairly stated in all material respects in relation to the consolidated financial statement from which it has been derived.

/s/ Cherry Bekaert LLP  
Charlotte, North Carolina  
March 10, 2016

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

There are no material changes to the disclosures made on this matter in the Company's Annual Report on Form 10-K for the fiscal year ended April 30, 2015.

**Item 4. Controls and Procedures**

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and with the participation of the Company's management, including the Chief Executive Officer ( CEO ) and Chief Financial Officer ( CFO ), of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of January 31, 2016. Based on that evaluation, the Company's management, including the CEO and CFO, concluded that, as of January 31, 2016, the Company's disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There was no significant change in the Company's internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

**Item 6. Exhibits**

- 3.4 Bylaws (As amended as of December 9, 2015) <sup>1</sup>
- 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 101.INS XBRL Instance Document
- 101.SCH XBRL Taxonomy Extension Schema Document
- 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
- 101.DEF XBRL Taxonomy Extension Definition Linkbase Document
- 101.LAB XBRL Taxonomy Extension Label Linkbase Document
- 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document

<sup>1</sup> Filed as an exhibit to the Kewaunee Scientific Corporation Current Report on Form 8-K (Commission File No. 0-5286) filed on December 10, 2015 and incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KEWAUNEE SCIENTIFIC CORPORATION  
(Registrant)

Date: March 10, 2016

By /s/ Thomas D. Hull III  
Thomas D. Hull III  
(As duly authorized officer and Vice President,  
Finance and Chief Financial Officer)